how does the body make glp 1 Science Behind GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements File:GLP-1 Signaling in the Body.jpg

Semaglutide reduced MACE by 20% compared to placebo over a median follow-up of 33 months

Medical research is advancing towards more personalised medical strategies, with growing acknowledgement that responses by patients to GLP-1 receptor agonists might differ markedly

When discussing treatment options, we outline limitations, risks, and alternatives

While effective for obesity management, ongoing research and vigilant patient monitoring are essential to address and mitigate potential risks associated with GLP-1 RAs [87] [88]

It is important to note that there is no definitive scientific consensus that these drugs directly cause pancreatitis, and the absolute risk appears to be low based on clinical trial data

In addition to glycemic control, the market is increasingly being shaped by demand for obesity management and cardiometabolic risk reduction